NORTH CHICAGO, Ill., Dec. 14, 2021 /PRNewswire/ — AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved Rinvoq® (upadacitinib; 15 mg, once daily) for the treatment of adults with active psoriatic…Original Article
Rinvoq (upadacitinib) Receives U.S. FDA Approval for Active Psoriatic Arthritis
